Public markets opened with a record day for biotech follow‑on financings as eight companies priced offerings that collectively raised more than $3.2 billion. Multiple issuers upsized their rounds, signaling strong investor demand for late‑stage and de‑risked stories despite broader market volatility. The haul included oversubscribed deals across therapeutics and platform companies, and the activity may ease near‑term capital constraints for sponsors advancing registrational programs or manufacturing scale‑up.